Oyster Point Pharma CEO and leadership

As President and CEO, Jeffrey Nau is responsible for developing novel, innovative therapies for diseases of the eye at Oyster Point Pharma. He is inspired by what people can accomplish when they harness their focus and determination to achieve a common goal. Each day, Jeff and his team work tirelessly to develop therapies to treat ocular surface disease. Jeff has over 20 years of experience working with private and publicly traded biotechnology, pharmaceutical, and medical device companies, including Ophthotech, Genentech, NeoVista, and Acuity Pharmaceuticals. During his tenure as Medical Science Director at Genentech, Jeff worked on the development of Lucentis®, a drug that transformed the treatment of retinal diseases for people around the world. Jeff leads by example in his current role as CEO of Oyster Point Pharma, promoting trust, collaboration, accountability and reliability to his multifaceted team. Outside of his responsibilities as CEO, Jeff serves on the board of BioNJ. Additionally, Jeff is passionate about public and population health, the empowerment of women in the workforce, and coaching youth in sports. Jeff holds a Master’s in Medical Science and a PhD in Public Health and Epidemiology.

Mark has been a CFO in the life science sector for over 30 years, working with senior executives and their boards.His eye care experience includes the successful exits of OptiMedica and Oculeve. Mark spent over 20 years with Guidant Corporation, where he was part of the senior management team and in its $1 billion IPO thru its exit in 2006 for $27 billion (by Boston Scientific and Abbott Labs). He has helped raise over $1.6 billion in equity and over $500 million in debt for public and private companies. Mark is currently a partner at partner at FLG Partners, LLC. He holds a BS in business administration (accounting) from San Francisco State University.

Daniel has nearly 15 years of experience in healthcare investing. Prior to joining Oyster Point Pharma, Daniel held positions of increasing responsibility in equity investing and fund management at Goldman Sachs Asset Management. Most recently he was a Managing Director and Portfolio Manager at Goldman Sachs, where he was a healthcare equity investor for various fund strategies. As a healthcare investor, Daniel focused on biotechnology, pharmaceutical, medical device and healthcare services companies and invested in a range of therapeutic categories, including ophthalmology. Daniel received an Executive M.B.A. from Columbia University and a B.A. in Economics from the University of Richmond.

John has 30 years of commercial experience in the pharmaceutical industry, including major ophthalmology businesses. He has a proven track record in taking programs from development to successful commercialization, and helping businesses achieve high growth. Prior to joining Oyster Point, John spent the past 2 years at Shire (now Takeda) as Group Vice President and Head of its ophthalmic business. During that time, he led a large, multidisciplinary team accountable for the growth of Shire’s first ophthalmic therapeutic, Xiidra ®, for treatment of dry eye.

As President and CEO, Jeffrey Nau is responsible for developing novel, innovative therapies for diseases of the eye at Oyster Point Pharma. He is inspired by what people can accomplish when they harness their focus and determination to achieve a common goal. Each day, Jeff and his team work tirelessly to develop therapies to treat ocular surface disease. Jeff has over 20 years of experience working with private and publicly traded biotechnology, pharmaceutical, and medical device companies, including Ophthotech, Genentech, NeoVista, and Acuity Pharmaceuticals. During his tenure as Medical Science Director at Genentech, Jeff worked on the development of Lucentis®, a drug that transformed the treatment of retinal diseases for people around the world. Jeff leads by example in his current role as CEO of Oyster Point Pharma, promoting trust, collaboration, accountability and reliability to his multifaceted team. Outside of his responsibilities as CEO, Jeff serves on the board of BioNJ. Additionally, Jeff is passionate about public and population health, the empowerment of women in the workforce, and coaching youth in sports. Jeff holds a Master’s in Medical Science and a PhD in Public Health and Epidemiology.

Mark has been a CFO in the life science sector for over 30 years, working with senior executives and their boards.His eye care experience includes the successful exits of OptiMedica and Oculeve. Mark spent over 20 years with Guidant Corporation, where he was part of the senior management team and in its $1 billion IPO thru its exit in 2006 for $27 billion (by Boston Scientific and Abbott Labs). He has helped raise over $1.6 billion in equity and over $500 million in debt for public and private companies. Mark is currently a partner at partner at FLG Partners, LLC. He holds a BS in business administration (accounting) from San Francisco State University.

As President and CEO, Jeffrey Nau is responsible for developing novel, innovative therapies for diseases of the eye at Oyster Point Pharma. He is inspired by what people can accomplish when they harness their focus and determination to achieve a common goal. Each day, Jeff and his team work tirelessly to develop therapies to treat ocular surface disease. Jeff has over 20 years of experience working with private and publicly traded biotechnology, pharmaceutical, and medical device companies, including Ophthotech, Genentech, NeoVista, and Acuity Pharmaceuticals. During his tenure as Medical Science Director at Genentech, Jeff worked on the development of Lucentis®, a drug that transformed the treatment of retinal diseases for people around the world. Jeff leads by example in his current role as CEO of Oyster Point Pharma, promoting trust, collaboration, accountability and reliability to his multifaceted team. Outside of his responsibilities as CEO, Jeff serves on the board of BioNJ. Additionally, Jeff is passionate about public and population health, the empowerment of women in the workforce, and coaching youth in sports. Jeff holds a Master’s in Medical Science and a PhD in Public Health and Epidemiology.

Mark has been a CFO in the life science sector for over 30 years, working with senior executives and their boards.His eye care experience includes the successful exits of OptiMedica and Oculeve. Mark spent over 20 years with Guidant Corporation, where he was part of the senior management team and in its $1 billion IPO thru its exit in 2006 for $27 billion (by Boston Scientific and Abbott Labs). He has helped raise over $1.6 billion in equity and over $500 million in debt for public and private companies. Mark is currently a partner at partner at FLG Partners, LLC. He holds a BS in business administration (accounting) from San Francisco State University.